MEA Platelet Rich Plasma Market

MEA Platelet-Rich Plasma Market Size (2023 to 2028)

The Middle East and Africa platelet-rich plasma market is estimated to be worth USD 19.55 million in 2023 and USD 32.65 million by 2028, growing at a CAGR of 10.8% from 2023 to 2028.

The awareness among the population of MEA regarding the benefits associated with platelet-rich plasma therapies in treating injuries among the aging population is slowly increasing, which is expected to drive the platelet-rich plasma market in MEA. In addition, the growing number of cosmetic and surgical operations and the increasing usage of platelet-rich plasma in various therapeutic applications are anticipated to fuel the market’s growth rate in the Middle East and Africa.  Furthermore, the growing usage of PRP among the patient population suffering from orthopedic diseases is expected to promote the PRP market growth in MEA. In addition, the growing incidence of sports injuries in MEA is anticipated to support this region’s growth rate.

However, the high costs associated with PRP therapies across the countries of the MEA region are one of the major factors hampering the regional market growth. In addition, factors such as side effects of PRP therapies and lack of favorable reimbursement policies further inhibit the growth rate of the MEA PRP market.

This research report on the Middle East and Africa platelet-rich plasma market has been segmented and sub-segmented into the following categories:

By Application: 

• Orthopedics
• Cosmetic Surgery
• Ophthalmic Surgery
• Neurosurgery

By Product: 

• Pure
• Leukocyte-Rich
• Leukocyte-Rich Fibrin

By Origin: 

• Homologous PRP
• Autologous PRP
• Allogeneic PRP    

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

During the forecast period, the MEA PRP is anticipated to have a moderate CAGR. The growing awareness of PRP benefits among healthcare providers and people, the rising prevalence of orthopedic diseases, the increasing incidence of sports injuries, and the growing geriatric population majorly drive the growth of the MEA PRP market. During the COVID pandemic, PRP therapies were used as an emergency treatment to avoid surgeries.

UAE and Saudi Arabia are expected to hold a considerable share of the MEA during the forecast period. This is due to the growing number of developments in the healthcare infrastructure, increasing adoption of advanced medical technologies, and increasing popularity of cosmetic surgeries. On the other hand, South Africa is also estimated to witness a healthy CAGR during the forecast period owing to the rising adoption of PRP therapies to treat orthopedic disease burden. In recent times, the usage of PRP in surgical procedures and orthopedic diseases has risen in South Africa. During the forecast period, the growing adoption of PRP therapies is expected to increase and result in market growth.

KEY MARKET PLAYERS:

Companies playing an important role in the MEA platelet-rich plasma market profiled in this report are DR. PRP AMERICA, LLC, Glofinn Oy, Zimmer Biomet, DePuy Synthes, Emcyte Corporation, Terumo BCT, Anthrex Inc, T-Biotechnology, and Stryker.